Multimodal oncological therapy comprising stents, brachytherapy, and regional chemotherapy for cholangiocarcinoma

Gut and Liver

Volumn 4, Issue SUPPL. 1, 2010, Pages

  Andrašina, Tomáš ^a   Válek, Vlastimil ^a   Pánek, Jiří ^a   Kala, Zdeněk ^a   Kiss, Igor ^b   Tuček, Štěpán ^b   Šlampa, Pavel ^b  

^a UNIVERSITY HOSPITAL BRNO   (Czech Republic)

^b MASARYK UNIVERSITY   (Czech Republic)

Author keywords

Brachytherapy; Cholangiocarcinoma; Infusions; Intra arterial; Stents

Indexed keywords

CISPLATIN; FLUOROURACIL; IODINATED POPPYSEED OIL;

AGED; ARTICLE; BILE DUCT CARCINOMA; BRACHYTHERAPY; CANCER CHEMOTHERAPY; CANCER SURVIVAL; CHEMOEMBOLIZATION; COMPUTER ASSISTED TOMOGRAPHY; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; MULTIMODALITY CANCER THERAPY; NUCLEAR MAGNETIC RESONANCE IMAGING; PERCUTANEOUS DRAINAGE; STENT;

EID: 77957591572     PISSN: 19762283     EISSN: None     Source Type: Journal    
DOI: 10.5009/gnl.2010.4.S1.S82     Document Type: Article

References (22)

1. Seyama Y, Makuuchi M. Current surgical treatment for bile duct cancer. World J Gastroenterol 2007;13:1505-1515.
2. Chung YE, Kim MJ, Park YN, et al. Varying appearances of cholangiocarcinoma: radiologic-pathologic correlation. Radiographics 2009;29:683-700.
3. Kaassis M, Boyer J, Dumas R, et al. Plastic or metal stents for malignant stricture of the common bile duct? Results of a randomized prospective study. Gastrointest Endosc 2003;57:178-182.
4. Lammer J, Hausegger KA, Fluckiger F, et al. Common bile duct obstruction due to malignancy: treatment with plastic versus metal stents. Radiology 1996;201:167-172.
5. Golfieri R, Giampalma E, Renzulli M, et al. Unresectable hilar cholangiocarcinoma: multimodality approach with percutaneous treatment associated with radiotherapy and chemotherapy. In Vivo 2006;20:757-760.
6. Eschelman DJ, Shapiro MJ, Bonn J, et al. Malignant biliary duct obstruction: long-term experience with Gianturco stents and combined-modality radiation therapy. Radiology 1996;200:717-724.
7. Valek V, Kysela P, Kala Z, Kiss I, Tomasek J, Petera J. Brachytherapy and percutaneous stenting in the treatment of cholangiocarcinoma: a prospective randomised study. Eur J Radiol 2007;62:175-179.
8. Kubicka S, Rudolph KL, Tietze MK, Lorenz M, Manns M. Phase II study of systemic gemcitabine chemotherapy for advanced unresectable hepatobiliary carcinomas. Hepato-gastroenterology 2001;48:783-789.
9. Kirchhoff T, Zender L, Merkesdal S, et al. Initial experience from a combination of systemic and regional chemotherapy in the treatment of patients with nonresectable cholangiocellular carcinoma in the liver. World J Gastroenterol 2005;11:1091-1095.
10. Burger I, Hong K, Schulick R, et al. Transcatheter arterial chemoembolization in unresectable cholangiocarcinoma: initial experience in a single institution. J Vasc Interv Radiol 2005;16:353-361.
11. Herber S, Otto G, Schneider J, et al. Transarterial chemoembolization (TACE) for inoperable intrahepatic cholangiocarcinoma. Cardiovasc Intervent Radiol 2007;30:1156-1165.
12. Tanaka N, Yamakado K, Nakatsuka A, Fujii A, Matsumura K, Takeda K. Arterial chemoinfusion therapy through an implanted port system for patients with unresectable intrahepatic cholangiocarcinoma - initial experience. Eur J Radiol 2002;41:42-48.
13. Jarnagin WR, Fong Y, DeMatteo RP, et al. Staging, resectability, and outcome in 225 patients with hilar cholangiocarcinoma. Ann Surg 2001;234:507-517.
14. Chan SY, Poon RT, Ng KK, Liu CL, Chan RT, Fan ST. Long-term survival after intraluminal brachytherapy for inoperable hilar cholangiocarcinoma: a case report. World J Gastroenterol 2005;11:3161-3164.
15. Lee KH, Lee DY, Kim KW. Biliary intervention for cholangiocarcinoma. Abdom Imaging 2004;29:581-589.
16. Forsmo HM, Horn A, Viste A, Hoem D, Ovrebo K. Survival and an overview of decision-making in patients with cholangiocarcinoma. Hepatobiliary Pancreat Dis Int 2008;7:412-417.
17. Singal AG, Rakoski MO, Salgia R, et al. The clinical presentation and prognostic factors for intrahepatic and extrahepatic cholangiocarcinoma in a tertiary care centre. Aliment Pharmacol Ther 2010;31:625-633.
18. Jarnagin WR, Bowne W, Klimstra DS, et al. Papillary phenotype confers improved survival after resection of hilar cholangiocarcinoma. Ann Surg 2005;241:703-712.
19. Nanashima A, Sumida Y, Abo T, et al. Relationship between pattern of tumor enhancement and clinicopathologic characteristics in intrahepatic cholangiocarcinoma. J Surg Oncol 2008;98:535-539.
20. Ito F, Cho CS, Rikkers LF, Weber SM. Hilar cholangiocarcinoma: current management. Ann Surg 2009;250: 210-218.
21. Aliberti C, Benea G, Tilli M, Fiorentini G. Chemoembolization (TACE) of unresectable intrahepatic cholangiocarcinoma with slow-release doxorubicin-eluting beads: preliminary results. Cardiovasc Intervent Radiol 2008;31:883-888.
22. Huether A, Hopfner M, Baradari V, Schuppan D, Scherubl H. Sorafenib alone or as combination therapy for growth control of cholangiocarcinoma. Biochem Pharmacol 2007; 73:1308-1317.